Aditya Bardia, M.P.H., M.B.B.S.

Physician Investigator (Cl)
Cancer Center, Mass General Research Institute
Associate Professor of Medicine
Harvard Medical School
MBBS All India Institute of Medical Sciences 2002
MPH University of Iowa College of Public Health 2005
antioxidants; aspirin; breast cancer; breast neoplasms; camptothecin; chemotherapy adjuvant; circulating tumor cells; complementary therapies; cytochrome p-450 cyp2d6; drug substitution; hot flashes; metastatic breast cancer; neoplasms multiple primary; neoplastic cells circulating; porphyria cutanea tarda; postmenopause; receptors estrogen; sex ratio; targeted therapy; tumor genotyping Dr. Bardia is a board-certified medical oncologist interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer. In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition, and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer. Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer. Dr. Bardia is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation.
Publications Clinical Profile

Lawrence House
10 North Grove Street
Boston, MA 02114